- Home
- GD vs BCTXW Comparison
GD vs BCTXW Comparison
Compare GD & BCTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GD
- BCTXW
- Stock Information
- Founded
- GD 2019
- BCTXW N/A
- Country
- GD United States
- BCTXW Canada
- Employees
- GD N/A
- BCTXW 12
- Industry
- GD Marine Transportation
- BCTXW Biotechnology: Pharmaceutical Preparations
- Sector
- GD Industrials
- BCTXW Health Care
- Exchange
- GD Nasdaq
- BCTXW Nasdaq
- Market Cap
- GD N/A
- BCTXW N/A
- IPO Year
- GD N/A
- BCTXW N/A
- Fundamental
- Price
- GD $268.84
- BCTXW $0.14
- Analyst Decision
- GD Buy
- BCTXW
- Analyst Count
- GD 19
- BCTXW 0
- Target Price
- GD $307.31
- BCTXW N/A
- AVG Volume (30 Days)
- GD 1.5M
- BCTXW N/A
- Earning Date
- GD 01-29-2025
- BCTXW N/A
- Dividend Yield
- GD 2.11%
- BCTXW N/A
- EPS Growth
- GD 9.52
- BCTXW N/A
- EPS
- GD 13.12
- BCTXW N/A
- Revenue
- GD $46,046,000,000.00
- BCTXW N/A
- Revenue This Year
- GD $15.93
- BCTXW N/A
- Revenue Next Year
- GD $5.93
- BCTXW N/A
- P/E Ratio
- GD $20.50
- BCTXW N/A
- Revenue Growth
- GD 11.07
- BCTXW N/A
- 52 Week Low
- GD $251.62
- BCTXW N/A
- 52 Week High
- GD $316.90
- BCTXW N/A
- Technical
- Relative Strength Index (RSI)
- GD 51.98
- BCTXW N/A
- Support Level
- GD $258.65
- BCTXW N/A
- Resistance Level
- GD $274.15
- BCTXW N/A
- Average True Range (ATR)
- GD 4.33
- BCTXW 0.00
- MACD
- GD 1.78
- BCTXW 0.00
- Stochastic Oscillator
- GD 67.99
- BCTXW 0.00
About BCTXW BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.